126 related articles for article (PubMed ID: 1694700)
1. Multiple myeloma with coexpression of myeloid and natural killer cell antigens.
Drach J; Gattringer C; Huber H
Blood; 1990 Jul; 76(1):265-6. PubMed ID: 1694700
[No Abstract] [Full Text] [Related]
2. Leu-19 in myeloma--a new role for an old antibody.
Wetter O; Brandhorst D; Reiter W
Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
[No Abstract] [Full Text] [Related]
3. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
[TBL] [Abstract][Full Text] [Related]
4. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells.
Drach J; Gattringer C; Huber H
Clin Exp Immunol; 1991 Mar; 83(3):418-22. PubMed ID: 1706237
[TBL] [Abstract][Full Text] [Related]
5. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells.
Handgretinger R; Schäfer HJ; Baur F; Frank D; Ottenlinger C; Bühring HJ; Niethammer D
Immunol Lett; 1993 Aug; 37(2-3):223-8. PubMed ID: 7505004
[TBL] [Abstract][Full Text] [Related]
6. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of CD56 and HLA/DR antigens in CD2+ cells from multiple myeloma patients.
Lapeña P; Prieto A; Garcia-Suarez J; Reyes E; San Miguel J; Jorda J; Alvarez-Mon M
Am J Hematol; 1994 Jun; 46(2):158-9. PubMed ID: 7513496
[No Abstract] [Full Text] [Related]
8. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.
Robillard N; Wuillème S; Lodé L; Magrangeas F; Minvielle S; Avet-Loiseau H
Leukemia; 2005 Nov; 19(11):2021-2. PubMed ID: 16167057
[No Abstract] [Full Text] [Related]
9. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry.
King MA; Radicchi-Mastroianni MA
Cytometry; 1996 Jun; 26(2):121-4. PubMed ID: 8817087
[TBL] [Abstract][Full Text] [Related]
10. Regulation of myeloid cell proliferation and survival by p75/AIRM1 and CD33 surface receptors.
Mingari MC; Vitale C; Romagnani C; Falco M; Moretta L
Adv Exp Med Biol; 2001; 495():55-61. PubMed ID: 11774609
[No Abstract] [Full Text] [Related]
11. Natural killer cell frequency and function in patients with monoclonal gammopathies.
Famularo G; D'Ambrosio A; Quintieri F; Di Giovanni S; Parzanese I; Pizzuto F; Giacomelli R; Pugliese O; Tonietti G
J Clin Lab Immunol; 1992; 37(3):99-109. PubMed ID: 1285130
[TBL] [Abstract][Full Text] [Related]
12. [Natural killer cells of different immunological phenotypes (CD16+, CD56+ and CD57+) in the blood of patients with insulin-dependent diabetes mellitus].
Shliakhovenko VS; Guzov MA; Milenko SE; Mikhaĭlovskaia EV; Kalinovskiĭ AK; Khodak AA; Zak KP
Vrach Delo; 1991 Feb; (2):36-9. PubMed ID: 1711735
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal antibody therapies for acute leukemia].
Takeshita A; Ono R
Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
[No Abstract] [Full Text] [Related]
14. Monoclonal antibodies in the treatment of myelogenous leukemias.
Scheinberg DA
Cancer Treat Res; 1993; 64():213-32. PubMed ID: 7680876
[No Abstract] [Full Text] [Related]
15. Natural killer cell activity in monoclonal gammopathies: relation to disease activity.
Osterborg A; Nilsson B; Björkholm M; Holm G; Mellstedt H
Eur J Haematol; 1990 Sep; 45(3):153-7. PubMed ID: 1699786
[TBL] [Abstract][Full Text] [Related]
16. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
17. An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia.
Anargyrou K; Paterakis G; Boutsis D; Politou M; Papadhimitriou SI; Siakandaris M; Vassiliadis J; Androulakis A; Meletis J; Rombos J; Tassiopoulou A; Vaiopoulos G
Eur J Haematol; 2003 Oct; 71(4):294-8. PubMed ID: 12950240
[TBL] [Abstract][Full Text] [Related]
18. A child case of CD34+, CD33-, HLA-DR-, CD7+, CD56+ stem cell leukemia with thymic involvement.
Nagata T; Higashigawa M; Nagai M; Zhang XL; Azuma E; Komada Y; Sakurai M
Leuk Res; 1996; 20(11-12):983-5. PubMed ID: 9009257
[TBL] [Abstract][Full Text] [Related]
19. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies.
Yamada O; Ichikawa M; Okamoto T; Park C; Motoji T; Mizoguchi H; Shibuya A
Br J Haematol; 2001 Apr; 113(1):153-60. PubMed ID: 11328295
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibodies to the HNK-1 antigen of human natural killers].
Atochina OV; Aksenova NN; Neustroev AP; Ivanov VA
Tsitologiia; 1994; 36(9-10):1006-11. PubMed ID: 7535492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
